Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017

GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Pipeline Assessemnt and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report identifies the key trends shaping and driving the global type 2 diabetes therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the market positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global type 2 diabetes sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the type 2 diabetes market to be worth $21.9 billion in 2009. The market is forecast to reach $36.1 billion by 2017 with a Compound Annual Growth Rate (CAGR) of 6% between 2010 and 2017. The main factors driving the growth of the market are the rapid growth in prevalence rates in the UK and the US, an increase in the utilization of premium priced drugs such as glitazones, an increase in prescriptions for combination drugs and an increase in the prevalence of obesity. Studies have found that obese people are three times more likely to be diagnosed with diabetes than normal people. The type 2 diabetes market has unmet needs in terms of safety and patient compliance. These unmet needs imply that the market is moderately served by the current treatment options and that significant potential exists for new entrants targeting these unmet needs.

GlobalData’s analysis reveals that there are over 251 molecules in various stages of the pipeline. Victoza, one of the promising drugs, is awaiting the US Food and Drug Administration’s (FDA) approval. The drug was approved by the European Medicines Agency (EMEA) in 2009. The late stage pipeline includes a few first-in-class and promising drugs such as dapagliflozin and D-Tagatose. These molecules differ from others as their site of action is different from that of the already marketed products. The major new classes of drugs include SGLT-2 inhibitors, 11β HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis inhibitors, interleukin-1β antagonists, Gastrin-Releasing Peptide (GRP) receptor agonists, GPR 119 agonists, TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptors.

Companies Mentioned:

GlaxoSmithKline
Hoffmann-La Roche
Novo Nordisk
Merck & Co., Inc.
Novartis AG
Sanofi-aventis
Eli Lilly and Company
[Studien Infos ausblenden]

1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Diabetes Therapeutics Market: Introduction 5
2.1 GlobalData Pipeline Report Guidance 5
3 Type 2 Diabetes Therapeutics: Market Characterization 6
3.1 Type 2 Diabetes Market Size 6
3.2 Type 2 Diabetes Market Forecast and CAGR 7
3.3 Drivers and Barriers for the Type 2 Diabetes Market 8
3.3.1 Drivers for Type 2 Diabetes Market 8
3.3.2 Restraints for Type 2 Diabetes Market 9
3.4 Opportunity and Unmet Need 10
3.4.1 Unmet Needs 10
3.4.2 Impact Analysis of Unmet Needs 10
3.5 Key Takeaway 12
4 Type 2 Diabetes Therapeutics Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Products in the Type 2 Diabetes Market 14
4.3.1 Actos (pioglitazone) 14
4.3.2 Avandia (rosiglitazone) 15
4.3.3 Januvia (sitagliptin) 16
4.3.4 Starlix (nateglinide) 17
4.3.5 Byetta (exenatide) 18
4.3.6 Lantus (insulin glargine) 19
4.3.7 Levemir (insulin detemir) 19
4.4 Key Takeaway 20
5 Type 2 Diabetes Therapeutics Market: Pipeline Assessment 21
5.1 Overview 21
5.2 Strategic Pipeline Assessment 21
5.2.1 Technology Trends Analytic Framework 21
5.3 Type 2 Diabetes Therapeutics – Promising Drugs under Clinical Development 22
5.4 Molecule Profile for Promising Drugs under Clinical Development 24
5.4.1 BMS-512148 (dapagliflozin) 24
5.4.2 Victoza 25
5.4.3 D-Tagatose 27
5.4.4 JNJ-28431754 (canagliflozin) 27
5.4.5 MB07803 28
5.5 Type 2 Diabetes Therapeutics Market—Clinical Pipeline by Mechanism of Action 30
5.6 Type 2 Diabetes Pipeline—Pipeline by Phase of Clinical Development 30
5.6.1 Type 2 Diabetes Therapeutics—Regulatory Filing and Phase III Clinical Pipeline 31
5.6.2 Type 2 Diabetes Therapeutics – Phase II Clinical Pipeline 32
5.6.3 Type 2 Diabetes Therapeutics – Phase I Clinical Pipeline 35
5.6.4 Type 2 Diabetes Therapeutics – Preclinical Pipeline 37
5.6.5 Type 2 Diabetes Therapeutics – Discovery Pipeline 38
5.7 Discontinued / Suspended Drugs for Type 2 Diabetes 38
5.8 Key Takeaway 38
6 Type 2 Diabetes Therapeutics Market: Implications for Future Market Competition 39
7 Type 2 Diabetes Therapeutics Market: Future Players in the Type 2 Diabetes Market 41
7.1 Introduction 41
7.2 GlaxoSmithKline 41
7.2.1 Company Overview 41
7.2.2 Business Description 42
7.2.3 Type 2 Diabetes Therapeutics Portfolio 42
7.3 Hoffmann-La Roche 43
7.3.1 Company Overview 43
7.3.2 Business Description 43
7.3.3 Type 2 Diabetes Therapeutics Portfolio 44
7.4 Novo Nordisk 44
7.4.1 Overview 44
7.4.2 Type 2 Diabetes Therapeutics Portfolio 45
7.5 Merck & Co., Inc. 46
7.5.1 Overview 46
7.5.2 Business Description 46
7.5.3 Type 2 Diabetes Therapeutics Portfolio 46
7.6 Novartis AG 47
7.6.1 Company Overview 47
7.6.2 Business Description 47
7.6.3 Type 2 Diabetes Therapeutics Portfolio 48
7.7 Sanofi-aventis 48
7.7.1 Company Overview 48
7.7.2 Business Description 49
7.7.3 Type 2 Diabetes Therapeutics Portfolio 49
7.8 Eli Lilly and Company 50
7.8.1 Overview 50
7.8.2 Type 2 Diabetes Therapeutics Portfolio 50
8 Type 2 Diabetes Therapeutics Market: Appendix 52
8.1 Definitions 52
8.2 Scope of Pipeline Research 52
8.3 Acronyms 52
8.4 Research Methodology 53
8.4.1 Coverage 53
8.4.2 Secondary Research 54
8.4.3 Forecasting 54
8.4.4 Primary Research 57
8.4.5 Expert Panel validation 58
8.5 Contact Us 58
8.6 Disclaimer 58
8.7 Sources 59
[Inhaltsverzeichnis ausblenden]

Table 1: Type 2 Diabetes Therapeutics, Global, Sales Value ($bn), 2001–2009 7
Table 2: Type 2 Diabetes Therapeutics, Global, Market Forecasts ($m), 2009–2017 8
Table 3: Type 2 Diabetes Market, Global, Most Promising Drugs Under Clinical Development, December 2010 22
Table 4: Type 2 Diabetes Therapeutics, Global, Regulatory Approval and Phase III Clinical Pipeline, 2010 31
Table 5: Type 2 Diabetes Therapeutics, Global, Phase II Clinical Development, 2010 32
Table 6: Type 2 Diabetes Therapeutics, Global, Phase I Clinical Development, 2010 35
Table 7: Type 2 Diabetes Therapeutics, Global, Preclinical Development, 2010 37
Table 8: Type 2 Diabetes Therapeutics, Global, Discovery Stage, 2010 38
Table 9: Type 2 Diabetes Therapeutics, Global, Discontinued drugs, 2010 38
Table 10: Type 2 Diabetes Therapeutics, Global, GlaxoSmithKline Products in the Market, 2010 42
Table 11: Type 2 Diabetes Therapeutics, Global, GlaxoSmithKline Pipeline Drugs, 2010 43
Table 12: Type 2 Diabetes Therapeutics, Global, Hoffmann-La Roche Pipeline Drugs, 2010 44
Table 13: Type 2 Diabetes Therapeutics, Global, Novo Nordisk Products in the Market, 2010 45
Table 14: Type 2 Diabetes Therapeutics, Global, Novo Nordisk Pipeline Drugs, 2010 45
Table 15: Type 2 Diabetes Therapeutics, Global, Merck & Co. Products in the Market, 2010 46
Table 16: Type 2 Diabetes Therapeutics, Global, Merck & Co. Pipeline Drugs, 2010 47
Table 17: Type 2 Diabetes Therapeutics, Global, Novartis Products in the Market, 2010 48
Table 18: Type 2 Diabetes Therapeutics, Global, Novartis Pipeline Drugs, 2010 48
Table 19: Type 2 Diabetes Therapeutics, Global, Sanofi-aventis Products in the Market, 2010 49
Table 20: Type 2 Diabetes Therapeutics, Global, Sanofi-aventis Pipeline Drugs, 2010 50
Table 21: Type 2 Diabetes Therapeutics, Global, Eli Lilly and Co. Products in the Market, 2010 50
Table 22: Type 2 Diabetes Therapeutics, Global, Eli Lilly & Co. Pipeline Drugs, 2010 51

Figure 1: Type 2 Diabetes Therapeutics, Global, Sales Value ($bn), 2001–2009 7
Figure 2: Type 2 Diabetes Therapeutics, Global, Sales Value ($bn), 2009–2017 8
Figure 3: Type 2 Diabetes Therapeutics, Global, Market Opportunity and Unmet Needs, 2010 11
Figure 4: Type 2 Diabetes Therapeutics, Global, Strategic Competitor Assessment of Major Marketed Products, 2010 14
Figure 5: Type 2 Diabetes Therapeutics, Global, Pipeline, Technology Trends Analytic Framework, 2010 21
Figure 6: Type 2 Diabetes Therapeutics, Global, Pipeline, Description of Technology Trends Analytic Framework, 2010 22
Figure 7: Type 2 Diabetes Therapeutics Market—Clinical Pipeline by Mechanism of Action, 2010 30
Figure 8: Type 2 Diabetes Therapeutics, Global, Pipeline by Phase of Clinical Development, 2010 30
Figure 9: Implications for Future Market Competition in the Type 2 Diabetes Market, 2010 39
Figure 10: Type 2 Diabetes Therapeutics Market, Global, Clinical Pipeline by Company, 2010 41
Figure 11: GlobalData Methodology, 2010 53
Figure 12: GlobalData Market Forecasting Model, 2010 56
[Tabellenverzeichnis ausblenden]